Biggest News Aggregation in the World
📰 Human Use News

Page 68 - Human Use News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis

– If Granted by the European Commission, Veklury will become the First and Only Authorized Antiviral Treatment Across All Stages of Renal Disease – ... | May 26, 2023
Foster City United States European Commission Development Program Gilead Sciences Gilead Sciences Inc

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

If approved for Europe, PYLCLARI¼ (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging

France General New York United States Sakir Mutevelic Gabriel Friedman Ross Bethell

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.Proven
United States France General Ross Bethell Pierre Curie Benoit Woessmer Sakir Mutevelic

Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

The European Commission decision is expected within 67 days of the CHMP opinion Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative
EtelÀuomen LÀi Scott Braunstein Sasha Damouni Ellis Gewinn Nur Marinus Pharmaceuticals European Union

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science